DiscoverDermasphere - The Dermatology Podcast141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV
141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

Update: 2024-09-30
Share

Description

Ruxolitinib vs triamcinolone -


Topical tofacitinib for LPP/FFA -


Locus of control in AD -


Low-dose naltrexone for LPP/FFA -


Alternative/complementary treatments for HSV -


Want to donate to the cause? Do so here!


Donate to the podcast: uofuhealth.org/dermasphere


Check out our video content on YouTube:


www.youtube.com/@dermaspherepodcast


and VuMedi!: www.vumedi.com/channel/dermasphere/


The University of Utah's Dermatology


ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -


⁠ Connect with us!


- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC


- Instagram: dermaspherepodcast


- Facebook: www.facebook.com/DermaspherePodcast/


- Check out Luke and Michelle’s other podcast,


SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our


friends at:


- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)


- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn


more dermatology!

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

Luke Johnson